U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07197060) titled 'Hypofractionated Radiotherapy With 3.5 Gy Per Fraction for Early Glottic Cancer' on Sept. 21.
Brief Summary: Early-stage glottic carcinoma (T1-T2N0M0) is typically managed with either transoral laser microsurgery or definitive radiotherapy, both providing excellent local control rates and voice preservation outcomes. Radiotherapy remains a widely adopted non-invasive option, particularly for patients with bilateral disease or poor surgical candidacy. Traditionally, conventional fractionation schemes of 2.0-2.25 Gy per fraction over 6-7 weeks have been standard; however, emerging evidence supports the use of hypofractionated radioth...